About
About Lexeo
Our approach
Team
Pipeline
Our pipeline
Publications & presentations
Programs
Friedreich ataxia programs
Cardiac programs
Arrhythmogenic сardiomyopathy
Desmoplakin cardiomyopathy
Hypertrophic cardiomyopathy
CNS programs
Alzheimer’s
Patients
Patient & community portal
Expanded access
Patient news
Careers
Contact
Investors
Patient News
LX2006
Friedreich ataxia cardiomyopathy (FA)
September 22, 2026
Lexeo Therapeutics' Friedreich Ataxia Portfolio Plans
Announcement
June 17, 2026
LX2006 Program Update: Publication in JAMA Cardiology of Phase I/II Data
Announcement
May 12, 2026
LX2006 Update in Lexeo First Quarter 2026 Earnings
Announcement
March 30, 2026
LX2006 Update in Lexeo Fourth Quarter and Full Year 2025 Earnings
Announcement
October 7, 2025
LX2006 Interim Clinical Data
Announcement
July 10, 2025
LX2006 Breakthrough Therapy Designation
Announcement
April 8, 2025
LX2006 Interim Clinical Data
Announcement
March 24, 2025
LX2006 Development Update
Announcement
LX2020
PKP2 arrhythmogenic сardiomyopathy (ACM)
August 6, 2026
LX2020 Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation
Announcement
May 12, 2026
LX2020 Update in Lexeo First Quarter 2026 Earnings
Announcement
March 30, 2026
LX2020 Update in Lexeo Fourth Quarter and Full Year 2025 Earnings
Announcement
January 14, 2026
LX2020 Interim Clinical Data
Announcement
March 24, 2025
LX2020 Interim Clinical Data
Announcement
Continue the story
Connect with our patient and community team
Visit the patient portal
